Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases.
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Orphazyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1TB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how 1TB performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 1TB performed against the German Market.
Price Volatility Vs. Market
How volatile is Orphazyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Orphazyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1TB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1TB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1TB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 1TB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1TB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1TB is overvalued based on its PB Ratio (10.8x) compared to the DE Biotechs industry average (3.5x).
How is Orphazyme forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1TB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1TB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1TB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1TB's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 1TB's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1TB is forecast to be unprofitable in 3 years.
How has Orphazyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1TB is currently unprofitable.
Growing Profit Margin: 1TB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1TB is unprofitable, and losses have increased over the past 5 years at a rate of -46% per year.
Accelerating Growth: Unable to compare 1TB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1TB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 1TB has a negative Return on Equity (-127.08%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Orphazyme's financial position?
Financial Position Analysis
Short Term Liabilities: 1TB's short term assets (DKK246.0M) exceed its short term liabilities (DKK44.4M).
Long Term Liabilities: 1TB's short term assets (DKK246.0M) exceed its long term liabilities (DKK9.7M).
Debt to Equity History and Analysis
Debt Level: 1TB is debt free.
Reducing Debt: 1TB had no debt 5 years ago.
Inventory Level: 1TB has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 1TB's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1TB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 1TB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -49.1% each year
What is Orphazyme's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1TB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 1TB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1TB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1TB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1TB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kim Stratton (57yo)
Ms. Kim Stratton has been Chief Executive Officer of Orphazyme A/S since October 1, 2019. Ms. Stratton has been a Director at Vifor Pharma AG since May 08, 2019. Ms. Stratton was the Head of International ...
|Chief Executive Officer||0.3yrs||no data||no data|
|Co-Founder & Chief Scientific Officer||0yrs||no data||no data|
|Chief Financial Officer||3.2yrs||no data||0.47% DKK2.1m|
|Chief Medical Officer||3.4yrs||no data||no data|
Experienced Management: 1TB's management team is considered experienced (3.2 years average tenure).
|Independent Director||3.1yrs||no data||no data|
|Independent Director||5.1yrs||no data||no data|
|Chairman||5.5yrs||no data||0.32% DKK1.4m|
|Deputy Chairman||3.1yrs||no data||0.30% DKK1.3m|
|Independent Director||10.1yrs||no data||no data|
|Independent Director||2.3yrs||no data||0.023% DKK102.5k|
|Independent Director||3.1yrs||no data||0.030% DKK130.8k|
|Independent Director||10.1yrs||no data||0.17% DKK754.1k|
Experienced Board: 1TB's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.
Orphazyme A/S's company bio, employee growth, exchange listings and data sources
- Name: Orphazyme A/S
- Ticker: 1TB
- Exchange: DB
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø3.312b
- Listing Market Cap: ø443.156m
- Shares outstanding: 27.04m
- Website: https://www.orphazyme.com
Number of Employees
- Orphazyme A/S
- Ole Maaløes Vej 3
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ORPHA||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Common Shares||DK||DKK||Nov 2017|
|1TB||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Nov 2017|
|0CUM||LSE (London Stock Exchange)||Yes||Common Shares||GB||DKK||Nov 2017|
|OZYM.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Nov 2017|
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases. It focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. The company’s lead candidate, Arimoclomol, is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. It also focuses on developing a series of heat-shock protein amplifying drugs. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 00:27|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.